CN110799546A - 重组双特异性抗体 - Google Patents
重组双特异性抗体 Download PDFInfo
- Publication number
- CN110799546A CN110799546A CN201880041765.6A CN201880041765A CN110799546A CN 110799546 A CN110799546 A CN 110799546A CN 201880041765 A CN201880041765 A CN 201880041765A CN 110799546 A CN110799546 A CN 110799546A
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- scfv
- bispecific antibody
- pdl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
提供了一种针对CTLA‑4和PDL‑1的重组双特异性抗体,编码抗体的核酸分子,包含该核酸分子的载体和宿主细胞,以及制备该抗体的方法。还提供了包含该双特异性抗体的药物组合物,以及该双特异性抗体在制备药物组合物中的用途。
Description
PCT国内申请,说明书已公开。
Claims (29)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017107814023 | 2017-09-01 | ||
CN201710781402 | 2017-09-01 | ||
PCT/CN2018/100971 WO2019042153A1 (zh) | 2017-09-01 | 2018-08-17 | 重组双特异性抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110799546A true CN110799546A (zh) | 2020-02-14 |
CN110799546B CN110799546B (zh) | 2023-01-24 |
Family
ID=65524891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880041765.6A Active CN110799546B (zh) | 2017-09-01 | 2018-08-17 | 重组双特异性抗体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11421029B2 (zh) |
EP (1) | EP3626745A4 (zh) |
JP (1) | JP7145895B2 (zh) |
KR (1) | KR20200041835A (zh) |
CN (1) | CN110799546B (zh) |
WO (1) | WO2019042153A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
HRP20230590T2 (hr) * | 2018-07-31 | 2024-02-16 | Pieris Pharmaceuticals Gmbh | Novi fuzijski protein specifičan za cd137 i pd-l1 |
BR112021022135A2 (pt) * | 2019-05-06 | 2023-02-28 | Univ Brown | Anticorpos biespecíficos contra chi3l1 e pd1 com efeitos citotóxicos mediados por célula t realçados sobre células de tumor |
CN114206931A (zh) * | 2019-09-30 | 2022-03-18 | 四川科伦博泰生物医药股份有限公司 | 抗pd-1抗体及其用途 |
US20230015590A1 (en) * | 2019-12-04 | 2023-01-19 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Bispecific fusion protein for tumor treatment |
WO2023143547A1 (zh) * | 2022-01-30 | 2023-08-03 | 百奥泰生物制药股份有限公司 | 抗cd28抗体及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201500132A1 (ru) * | 2012-07-13 | 2015-08-31 | Роше Гликарт Аг | Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний |
CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
CN104987421A (zh) * | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
WO2017106061A1 (en) * | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
CN106967172A (zh) * | 2016-08-23 | 2017-07-21 | 中山康方生物医药有限公司 | 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途 |
CN107108747A (zh) * | 2015-01-08 | 2017-08-29 | 苏州康宁杰瑞生物科技有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
WO2018091739A1 (en) * | 2016-11-21 | 2018-05-24 | Alligator Bioscience Ab | Bispecific polypeptides to gitr and ctla-4 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
WO2015048312A1 (en) * | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JP2019506863A (ja) | 2016-02-02 | 2019-03-14 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | Pd−l1及びkdrに対する二重結合タンパク質 |
NZ743881A (en) * | 2016-02-06 | 2023-11-24 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
PE20190510A1 (es) * | 2016-06-13 | 2019-04-10 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos |
US10793632B2 (en) * | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN107082812B (zh) * | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
-
2018
- 2018-08-17 KR KR1020197038632A patent/KR20200041835A/ko active IP Right Grant
- 2018-08-17 WO PCT/CN2018/100971 patent/WO2019042153A1/zh unknown
- 2018-08-17 EP EP18851360.0A patent/EP3626745A4/en active Pending
- 2018-08-17 JP JP2019572582A patent/JP7145895B2/ja active Active
- 2018-08-17 US US16/624,408 patent/US11421029B2/en active Active
- 2018-08-17 CN CN201880041765.6A patent/CN110799546B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201500132A1 (ru) * | 2012-07-13 | 2015-08-31 | Роше Гликарт Аг | Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний |
CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
CN107108747A (zh) * | 2015-01-08 | 2017-08-29 | 苏州康宁杰瑞生物科技有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
CN104987421A (zh) * | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
WO2017106061A1 (en) * | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
CN106967172A (zh) * | 2016-08-23 | 2017-07-21 | 中山康方生物医药有限公司 | 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途 |
WO2018091739A1 (en) * | 2016-11-21 | 2018-05-24 | Alligator Bioscience Ab | Bispecific polypeptides to gitr and ctla-4 |
Also Published As
Publication number | Publication date |
---|---|
US20200216538A1 (en) | 2020-07-09 |
EP3626745A1 (en) | 2020-03-25 |
EP3626745A4 (en) | 2021-03-17 |
WO2019042153A1 (zh) | 2019-03-07 |
JP2020534791A (ja) | 2020-12-03 |
US11421029B2 (en) | 2022-08-23 |
JP7145895B2 (ja) | 2022-10-03 |
KR20200041835A (ko) | 2020-04-22 |
CN110799546B (zh) | 2023-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7425604B2 (ja) | 抗ctla4-抗pd-1二機能性抗体、その医薬組成物および使用 | |
KR102340832B1 (ko) | 항 pd-1 항체 및 그의 용도 | |
TWI751981B (zh) | 抗pd-1抗體及組成物 | |
CN110799546B (zh) | 重组双特异性抗体 | |
JP7401538B2 (ja) | 抗cldn18.2抗体およびその使用 | |
CN108373504B (zh) | Cd24特异性抗体和抗cd24-car-t细胞 | |
CN113166246A (zh) | 一种抗体及其用途 | |
CN111542546B (zh) | 抗lag-3抗体及其用途 | |
CN110734493B (zh) | 抗pd-1抗体及其用途 | |
EP4039704A1 (en) | Anti-pd-1 antibody and use thereof | |
JP2023525827A (ja) | 抗cd73抗体およびその使用 | |
JP2022547081A (ja) | 抗cd73抗体 | |
CN116323667A (zh) | 结合PSMA和γ-δT细胞受体的抗体 | |
US20240002544A1 (en) | Cd28 bispecific antibodies for targeted t cell activation | |
WO2022171080A1 (zh) | 抗cd112r抗体及其用途 | |
WO2022127066A1 (zh) | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 | |
CN110959015A (zh) | 双特异性重组蛋白 | |
JP2023546508A (ja) | 抗tigit抗体、その医薬組成物及び用途 | |
CN115715297A (zh) | 抗flt3抗体和组合物 | |
WO2024007672A1 (zh) | 特异性结合cd24的抗体及其用途 | |
TWI789679B (zh) | 抗人程序性死亡配體-1(pd-l1)的抗體及其用途 | |
WO2023246574A1 (zh) | 靶向gpc3的抗体及其用途 | |
WO2024094003A1 (zh) | 抗ccr8的抗体及其用途 | |
WO2022268168A1 (zh) | 靶向lag-3和pd-l1的新型双特异抗体及其应用 | |
TW202246340A (zh) | 抗ctla-4抗體及其應用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40024029 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |